Linked e-resources
Details
Table of Contents
Preface; Contents; Contributors; Chapter 1: Antibody Therapies in Cancer; 1 Historical Review of Antibody Therapeutics in Cancer; 1.1 Characteristics of Antibody; 1.2 Development of Antibody Therapies for Cancer; 1.3 Classes of Antibody Therapeutics in Cancer; 2 Tumor-Targeted Antibody Therapies; 2.1 An Outline of Tumor-Targeted Antibody Therapeutics; 2.1.1 Epidermal Growth Factor Receptor; 2.1.2 Human Epidermal Growth Factor Receptor; 2.1.3 VEGF; 2.1.4 Hematopoietic Differentiation Antigens; 2.1.4.1 CD20; 2.1.4.2 CD52; 2.1.4.3 CD19; 2.1.4.4 CD30
2.2 Clinical Efficacy of Tumor-Targeted Antibody Therapeutics2.2.1 Hematological Malignancies; 2.3 Gastrointestinal Tumors; 2.3.1 Breast Cancer; 2.3.2 Lung Cancer; 2.3.3 Head and Neck Cancers; 2.3.4 Genitourinary; 2.4 Mechanisms Underlying the Antitumor Activity of Tumor-Targeted Antibodies; 2.4.1 Blockade of Ligand Binding and Signaling; 2.4.2 Antibody-Dependent Cellular Cytotoxicity and Phagocytosis; 2.4.3 Complement-Dependent Cytotoxicity; 2.4.4 Induction of T-Cell Immunity Through Cross-Presentation; 2.5 Immunoconjugates: Targeting Cytotoxic Agents to Tumor Cells
2.5.1 Antibody-Drug Conjugates2.5.2 Radioimmunoconjugates; 3 Immunomodulating Antibody Therapies; 3.1 Therapy Targeting Immune Checkpoints in Cancer; 3.1.1 CTLA-4; 3.1.1.1 Biology of CTLA-4 Pathway; 3.1.1.2 Clinical Impact of CTLA-4 Blockade; 3.1.1.3 The Unique Kinetics of Responses to Ipilimumab; 3.1.1.4 The Biomarkers for Responses to Ipilimumab; 3.1.1.5 Side Effects of CTLA-4 Blockade; 3.1.2 PD-1; 3.1.2.1 Biology of PD-1 Pathway; 3.1.2.2 Expression of PD-1 and PD-L1 in Tumors; 3.1.2.3 Clinical Impact of Drugs Blocking PD-1; 3.1.2.4 Predictive Biomarkers for PD-1 Inhibitors
3.1.2.5 The Side Effects of PD-1 Blockade3.1.2.6 Antitumor Mechanism of Checkpoint Blockade; 3.1.3 Other Potential Checkpoints; 3.1.3.1 LAG-3; 3.1.3.2 TIM-3; 3.1.3.3 B7-H3 and B7-H4; 3.1.3.4 Killer Inhibitory Receptors; 3.1.3.5 The Mechanisms of Evading Phagocytosis by Tumor Cells; 3.2 Immunostimulating Antibody Therapy; 3.2.1 TNFR Superfamily; 3.2.1.1 4-1BB; 3.2.1.2 OX40; 3.2.1.3 CD40; 3.2.2 Bispecific Antibodies; 3.2.3 Immunocytokines; 4 Combination Therapy of Antibodies; 4.1 Antibody Therapeutics in Combination with Conventional Therapies
4.1.1 Combination of Tumor-Targeting Antibodies with Cytotoxic Chemotherapies4.1.2 Combination of Tumor-Targeting Antibodies with Radiation Therapy; 4.1.3 Combination of Immune Checkpoint Blockade with Conventional Therapies; 4.2 Antibody Therapeutics in Combination with Immunotherapies; 4.2.1 Combination of Multiple Checkpoint Blockades; 4.2.2 Combination of Checkpoint Blockade with Other Immunotherapies; 5 Future Prospects; References; Chapter 2: Biological Response Modifier in Cancer Immunotherapy; 1 Introduction; 2 Toll-Like Receptor Signaling and Agonists; 2.1 Toll-Like Receptors (TLRs)
2.2 Clinical Efficacy of Tumor-Targeted Antibody Therapeutics2.2.1 Hematological Malignancies; 2.3 Gastrointestinal Tumors; 2.3.1 Breast Cancer; 2.3.2 Lung Cancer; 2.3.3 Head and Neck Cancers; 2.3.4 Genitourinary; 2.4 Mechanisms Underlying the Antitumor Activity of Tumor-Targeted Antibodies; 2.4.1 Blockade of Ligand Binding and Signaling; 2.4.2 Antibody-Dependent Cellular Cytotoxicity and Phagocytosis; 2.4.3 Complement-Dependent Cytotoxicity; 2.4.4 Induction of T-Cell Immunity Through Cross-Presentation; 2.5 Immunoconjugates: Targeting Cytotoxic Agents to Tumor Cells
2.5.1 Antibody-Drug Conjugates2.5.2 Radioimmunoconjugates; 3 Immunomodulating Antibody Therapies; 3.1 Therapy Targeting Immune Checkpoints in Cancer; 3.1.1 CTLA-4; 3.1.1.1 Biology of CTLA-4 Pathway; 3.1.1.2 Clinical Impact of CTLA-4 Blockade; 3.1.1.3 The Unique Kinetics of Responses to Ipilimumab; 3.1.1.4 The Biomarkers for Responses to Ipilimumab; 3.1.1.5 Side Effects of CTLA-4 Blockade; 3.1.2 PD-1; 3.1.2.1 Biology of PD-1 Pathway; 3.1.2.2 Expression of PD-1 and PD-L1 in Tumors; 3.1.2.3 Clinical Impact of Drugs Blocking PD-1; 3.1.2.4 Predictive Biomarkers for PD-1 Inhibitors
3.1.2.5 The Side Effects of PD-1 Blockade3.1.2.6 Antitumor Mechanism of Checkpoint Blockade; 3.1.3 Other Potential Checkpoints; 3.1.3.1 LAG-3; 3.1.3.2 TIM-3; 3.1.3.3 B7-H3 and B7-H4; 3.1.3.4 Killer Inhibitory Receptors; 3.1.3.5 The Mechanisms of Evading Phagocytosis by Tumor Cells; 3.2 Immunostimulating Antibody Therapy; 3.2.1 TNFR Superfamily; 3.2.1.1 4-1BB; 3.2.1.2 OX40; 3.2.1.3 CD40; 3.2.2 Bispecific Antibodies; 3.2.3 Immunocytokines; 4 Combination Therapy of Antibodies; 4.1 Antibody Therapeutics in Combination with Conventional Therapies
4.1.1 Combination of Tumor-Targeting Antibodies with Cytotoxic Chemotherapies4.1.2 Combination of Tumor-Targeting Antibodies with Radiation Therapy; 4.1.3 Combination of Immune Checkpoint Blockade with Conventional Therapies; 4.2 Antibody Therapeutics in Combination with Immunotherapies; 4.2.1 Combination of Multiple Checkpoint Blockades; 4.2.2 Combination of Checkpoint Blockade with Other Immunotherapies; 5 Future Prospects; References; Chapter 2: Biological Response Modifier in Cancer Immunotherapy; 1 Introduction; 2 Toll-Like Receptor Signaling and Agonists; 2.1 Toll-Like Receptors (TLRs)